<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518607</url>
  </required_header>
  <id_info>
    <org_study_id>14-019</org_study_id>
    <secondary_id>2015-000489-73</secondary_id>
    <secondary_id>MGB-BP-3-101</secondary_id>
    <nct_id>NCT02518607</nct_id>
  </id_info>
  <brief_title>Safety, Blood Levels and Effects of MGB-BP-3</brief_title>
  <official_title>A Single-centre, Double-blind, Placebo-controlled, Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending Doses of MGB-BP-3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MGB Biopharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hammersmith Medicines Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovate UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge Regulatory Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phases Clinical Research Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synlab Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Viapath</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Analytical Services International Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MGB Biopharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety and tolerability aspects of oral MGB-BP-3, a treatment for&#xD;
      Clostridium difficile infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Short Title: Safety, blood levels and effects of MGB-BP-3&#xD;
&#xD;
      Trial medication MGB-BP-3 is a new class of antibacterial agent that binds selectively to the&#xD;
      bacterial DNA minor groove and possesses strong bactericidal in vitro and in vivo activity&#xD;
      against Clostridium difficile (C. difficile). In addition to its activity against C.&#xD;
      difficile MGB-BP-3 has very strong activity against all other Gram-positive bacteria tested,&#xD;
      including susceptible and resistant Staphylococcus aureus, Streptococcus and Enterococcus.&#xD;
&#xD;
      MGB-BP-3 is being developed for the treatment of C. difficile infections (CDI).&#xD;
&#xD;
      Objectives Primary: To assess the safety and tolerability of single and repeated oral doses&#xD;
      of MGB-BP-3 in healthy men Secondary: To assess the pharmacokinetics (PK) of single and&#xD;
      repeated oral doses of MGB-BP-3 in healthy men&#xD;
&#xD;
      Type of trial This trial will be done in 2 parts, as follows. Part A: Phase I, double-blind,&#xD;
      randomised, placebo-controlled, crossover, single ascending-dose trial in healthy men.&#xD;
&#xD;
      Part B: Phase I, double-blind, randomised, placebo-controlled, sequential-group, repeated&#xD;
      ascending-dose trial in healthy men.&#xD;
&#xD;
      Trial population Total up to 40 healthy men (excluding replacement subjects): 16 subjects in&#xD;
      Part A and 24 subjects in Part B.&#xD;
&#xD;
      Age 18-45 years Principal inclusion criteria Normotensive male, with a body mass index (BMI)&#xD;
      of 18.0-30.9 kg/m2; deemed healthy on the basis of a clinical history, physical examination,&#xD;
      electrocardiogram (ECG), vital signs, and laboratory tests of blood and urine; willing to use&#xD;
      reliable contraception; able to give fully informed written consent.&#xD;
&#xD;
      Principal exclusion criteria Positive tests for hepatitis B &amp; C, HIV; severe adverse reaction&#xD;
      to any drug; drug or alcohol abuse; smoke more than 5 cigarettes (or use of equivalent&#xD;
      tobacco or nicotine products) daily; over-the-counter medication within previous 7 days (with&#xD;
      the exception of paracetamol), or prescribed medication during previous 28 days;&#xD;
      participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL&#xD;
      blood, within the previous 3 months; vital signs outside the acceptable range; clinically&#xD;
      relevant abnormal findings at the screening assessment; acute or chronic illness; clinically&#xD;
      relevant abnormal medical history or concurrent medical condition; possibility that volunteer&#xD;
      will not cooperate.&#xD;
&#xD;
      Trial design and methods Part A Part A is a randomised, double-blind, placebo-controlled,&#xD;
      cross-over, single ascending-dose trial in 16 healthy men. Subjects will be enrolled in 2&#xD;
      groups of 8 (Groups 1 and 2). Each subject will have 3 study sessions - they will receive a&#xD;
      single oral dose of MGB-BP-3 in up to 3 study sessions; 6 volunteers will receive matching&#xD;
      placebo in 1 study session.&#xD;
&#xD;
      So, at each dose level, 6 subjects will be randomised to receive MGB-BP-3 and 2 subjects will&#xD;
      be randomised to receive placebo.&#xD;
&#xD;
      There will be a washout period of at least 4 days between doses for each subject, and an&#xD;
      interval of at least 6 days between the last dose in Group 1 and the first dose in Group 2.&#xD;
&#xD;
      The investigator and sponsor will review the safety and tolerability data for each dose level&#xD;
      before increasing the dose. The dose will only be escalated if the safety and tolerability of&#xD;
      the previous dose level are acceptable. The planned dose level may be changed, based on&#xD;
      emerging safety and tolerability data - a dose level may be repeated or a lower dose tested.&#xD;
      The maximum dose tested will not exceed 2000 mg MGB-BP-3, which is 2-fold lower than the&#xD;
      NOAEL (no observed adverse effect level) in male dog.&#xD;
&#xD;
      Because MGB-BP-3 has never been given to humans before, the first dose level will be&#xD;
      staggered: 2 leading subjects will be dosed no later than the day before the remaining&#xD;
      subjects in the group are dosed. The leading subjects will be dosed at intervals of at least&#xD;
      10 minutes, and the remaining subjects also at intervals of at least 10 minutes. To maintain&#xD;
      the blind nature of the study, 1 of the leading subjects will be randomised to receive&#xD;
      MGB-BP-3 and the other to placebo.&#xD;
&#xD;
      Part A is considered to be the 'first in human' portion of the study, so GP (General&#xD;
      Practioner) replies must be obtained for the subjects in Part A. Subjects will be screened&#xD;
      during the 4 weeks before their first dose of trial medication. In each of their 3 study&#xD;
      sessions, subjects will be resident on the ward from the day before dosing (Day -1), until&#xD;
      completion of procedures at 72 h after their dose of trial medication (Day 4). Subjects will&#xD;
      attend a follow-up visit at 7-10 days after their dose of trial medication.&#xD;
&#xD;
      Part B Part B is a randomised, double-blind, placebo-controlled, sequential-group, repeated&#xD;
      ascending-dose trial in 24 healthy men.&#xD;
&#xD;
      The sponsor and investigator will select 3 dose levels to be tested in Part B, based on&#xD;
      available safety and tolerability data from Part A. The highest total daily dose tested in&#xD;
      Part B will not exceed the highest dose in Part A that was acceptably tolerated and for which&#xD;
      there were no safety concerns. Part B can start before Part A has finished, provided that the&#xD;
      total daily dose to be given (or a higher dose) has previously been shown to be acceptably&#xD;
      tolerated and safe in Part A.&#xD;
&#xD;
      Subjects will be enrolled in 3 groups of 8 (Groups 3-5). Each subject will have 1 study&#xD;
      session, in which they will receive twice-daily oral doses of MGB-BP-3, or matching placebo,&#xD;
      for 9 days (Days 1-9) and a single dose on the morning of Day 10.&#xD;
&#xD;
      In each group, 6 subjects will be randomised to receive MGB-BP-3 and 2 subjects will be&#xD;
      randomised to receive placebo. Subjects in each group will be dosed at intervals of at least&#xD;
      10 minutes.&#xD;
&#xD;
      For each ascending dose level, there'll be a gap of least 6 days between the final dose of&#xD;
      the previous group and the first dose of the next group. The investigator and sponsor will&#xD;
      review safety and tolerability data for each dose level before increasing the dose. The dose&#xD;
      will be escalated only if the safety and tolerability of the previous dose level are&#xD;
      acceptable. The planned doses may be changed, depending on the safety and tolerability of&#xD;
      previous doses - a dose level may be repeated or a lower dose tested.&#xD;
&#xD;
      Subjects will be screened within 4 weeks before their first dose of trial medication. They&#xD;
      will be resident on the ward from admission on Day -2 until completion of procedures at 72 h&#xD;
      after their final dose of trial medication (Day 13). They will attend a follow-up visit at&#xD;
      7-10 days after their final dose of trial medication.&#xD;
&#xD;
      Methods: Parts A and B&#xD;
&#xD;
      The following assessments will be made:&#xD;
&#xD;
      Safety: laboratory assessments (routine haematology, biochemistry and urinalysis), physical&#xD;
      examination, 12-lead ECG, telemetry (Part A only) faecal occult blood, intestinal&#xD;
      permeability (the ratio of lactulose to mannitol excreted in urine, Part B only), faecal&#xD;
      flora (Part B only), vital signs, and adverse events.&#xD;
&#xD;
      Tolerability: adverse events. Pharmacokinetic: blood samples for assay of MGB-BP-3 and&#xD;
      possible metabolites will be taken before, and frequently up to 48 h after dosing in Part A,&#xD;
      and up to 12 h after subjects' morning dose on Day 1 and up to 48 h after dosing on Day 10 in&#xD;
      Part B. In addition, in Part B, a blood sample will be taken before the morning dose on each&#xD;
      of Days 2-9. Urine will be collected for 24 h after each dose for assay of MGB-BP-3 in Part&#xD;
      A, and for 12 h after the morning dose on Day 1 and 10 (Part B only). Faecal samples will be&#xD;
      collected daily until 72 h after subjects' (final) dose for assay of MGB-BP-3 in each study&#xD;
      session, and in Part B for 24 h after dosing on Days 1 and 5.&#xD;
&#xD;
      Primary variables Safety: vital signs, ECG, telemetry (Part A only), physical examination,&#xD;
      laboratory safety tests, faecal occult blood, intestinal permeability (Part B only), faecal&#xD;
      flora (Part B only) Tolerability: adverse events&#xD;
&#xD;
      Secondary variables&#xD;
&#xD;
      Pharmacokinetics: PK parameters of MGB-BP-3:&#xD;
&#xD;
      Cmax, tmax and if appropriate t½, AUC0-t, AUC0-∞, Ctrough, AUC 0-τ (Part B), Vd/f (in Part A&#xD;
      and Vdss/f in Part B) and CL/f (in Part A and CLss/f in Part B) in plasma Ae0-24 (Part A),&#xD;
      Ae0-τ (Part B) and CLr in urine The amount of MGB-BP-3 excreted in faeces.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of single and repeated oral doses of MGB-BP-3 in healthy men</measure>
    <time_frame>4 months</time_frame>
    <description>Safety Assessment - Composite Metrics: vital signs, ECG, telemetry (Part A only), physical examination, laboratory safety tests, faecal occult blood, intestinal permeability (absorptive capacity test using differential sugar absorption with the urine sugars measured using LC-MS, Part B only), faecal flora (Part B only) and Tolerability (AE's &amp; SAE's)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetics (PK) of single and repeated oral doses of MGB-BP-3 in healthy men</measure>
    <time_frame>4 months</time_frame>
    <description>PK parameters of MGB-BP-3 - Composite Metrics Cmax, tmax and if appropriate t½, AUC0-t, AUC0-∞, Ctrough, AUC 0-τ (Part B), Vd/f (in Part A and Vdss/f in Part B) and CL/f (in Part A and CLss/f in Part B) in plasma Ae0-24 (Part A), Ae0-τ (Part B) and CLr in urine The amount of MGB-BP-3 excreted in faeces.</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1, Session 1, Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lowest dose of SAD:&#xD;
MGB-BP-3, 250 mg liquid filled enterically coated capsule, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1, Session 2, Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation SAD:&#xD;
MGB-BP-3, 2X250 mg liquid filled enterically coated capsule, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1, Session 3, Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation SAD MGB-BP-3, 3X250 mg liquid filled enterically coated capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, Session 1, Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation SAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, Session 2, Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation SAD MGB-BP-3, 5X250 mg liquid filled enterically coated capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, Session 3, Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation SAD MGB-BP-3, 6X250 mg liquid filled enterically coated capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3, Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lowest dose of MAD MGB-BP-3, 2X250 mg liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4, Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation MAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5, Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation MAD MGB-BP-3, 8X250 mg liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1, Session 1, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lowest dose of SAD:&#xD;
Placebo, 1 liquid filled enterically coated capsule, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1, Session 2, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 2 liquid filled enterically coated capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1, Session 3, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 3 liquid filled enterically coated capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, Session 1, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 4 liquid filled enterically coated capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, Session 2, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 5 liquid filled enterically coated capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, Session 3, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 6 liquid filled enterically coated capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 4 liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 8 liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGB-BP-3</intervention_name>
    <description>Treatment of CDI</description>
    <arm_group_label>Group 1, Session 1, Active</arm_group_label>
    <arm_group_label>Group 1, Session 2, Active</arm_group_label>
    <arm_group_label>Group 1, Session 3, Active</arm_group_label>
    <arm_group_label>Group 2, Session 1, Active</arm_group_label>
    <arm_group_label>Group 2, Session 2, Active</arm_group_label>
    <arm_group_label>Group 2, Session 3, Active</arm_group_label>
    <arm_group_label>Group 3, Active</arm_group_label>
    <arm_group_label>Group 4, Active</arm_group_label>
    <arm_group_label>Group 5, Active</arm_group_label>
    <other_name>MGB-BP-3-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group 1, Session 1, Placebo</arm_group_label>
    <arm_group_label>Group 1, Session 2, Placebo</arm_group_label>
    <arm_group_label>Group 1, Session 3, Placebo</arm_group_label>
    <arm_group_label>Group 2, Session 1, Placebo</arm_group_label>
    <arm_group_label>Group 2, Session 2, Placebo</arm_group_label>
    <arm_group_label>Group 2, Session 3, Placebo</arm_group_label>
    <arm_group_label>Group 3, Placebo</arm_group_label>
    <arm_group_label>Group 4, Placebo</arm_group_label>
    <arm_group_label>Group 5, Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0-30.9 kg/m2&#xD;
&#xD;
          -  Normal blood pressure&#xD;
&#xD;
          -  healthy on the basis of a clinical history &amp; physical examination&#xD;
&#xD;
          -  Normal ECG&#xD;
&#xD;
          -  Normal vital signs&#xD;
&#xD;
          -  Normal laboratory tests of blood and urine&#xD;
&#xD;
          -  Willing to use reliable contraception&#xD;
&#xD;
          -  Able to give fully informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive tests for hepatitis B &amp; C&#xD;
&#xD;
          -  Positive tests for HIV&#xD;
&#xD;
          -  Severe adverse reaction to any drug&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Smoke more than 5 cigarettes (or use of equivalent tobacco or nicotine products) daily&#xD;
&#xD;
          -  Received over-the-counter medication within previous 7 days (with the exception of&#xD;
             paracetamol)&#xD;
&#xD;
          -  Prescribed medication during previous 28 days&#xD;
&#xD;
          -  Participation in other clinical trials of unlicensed medicines&#xD;
&#xD;
          -  Loss of more than 400 mL blood, within the previous 3 months&#xD;
&#xD;
          -  Vital signs outside the acceptable range&#xD;
&#xD;
          -  Clinically relevant abnormal findings at the screening assessment&#xD;
&#xD;
          -  Acute or chronic illness&#xD;
&#xD;
          -  Clinically relevant abnormal medical history or concurrent medical condition&#xD;
&#xD;
          -  Possibility that volunteer will not cooperate.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Boyce, Various</last_name>
    <role>Principal Investigator</role>
    <affiliation>HMR London</affiliation>
  </overall_official>
  <link>
    <url>http://www.mgb-biopharma.com</url>
    <description>MGB Biopharma Limited</description>
  </link>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety and Tolerability</keyword>
  <keyword>Male Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

